Position Papers
25th March 2024
Environmental Sustainability: The EIPG perspective
EIPG has started the preparation of a document that analyses the main critical areas of the entire production process of a medicinal product and sets out its position on the interventions considered a priority in a perspective of changes that will lead to the inclusion of new methods alternative material resources and will require new skills.
24th November 2023
The drug shortage situation – EIPG’s point of view
Everyone in industry agrees that problems of shortages are complex with no quick solutions. Several factors can be identified as being at the root of the shortage of medicines, some of which intersect with each other, mainly concerning aspects with technical, qualitative, regulatory, forecasting, supply, speculative and economic implications.
8th November 2023
EIPG’s position paper on the revised Pharmaceutical legislation
2nd May 2017
EIPG Comments on the European Medicines Agency draft Questions and answers on implementation of risk based prevention of cross contamination in production and ‘Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities’ (EMA/CHMP/CVMP/SWP/169430/2012).
24th November 2015
EIPG Feedback on the European Commission public consultation on a Commission Delegated Act on principles and guidelines on good manufacturing practice for investigational medicinal products and on inspection procedures, pursuant to the first subparagraph of Article 63(1) of Regulation (EU) No 536/2014 and Detailed Commission guidelines on good manufacturing practice for investigational medicinal products for human use, pursuant to the second subparagraph of Article 63(1) of Regulation (EU) No 536/2014.
31st December 2011
Comments from the European Industrial Pharmacists Group on the Commission’s Revised Guidelines on Good Distribution Practice of Medicinal Products for Human Use.
27th October 2008
